Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. News
Spyre Therapeutics, Inc. Quantitative Score
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Spyre Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Spyre Therapeutics, Inc. Financials
Table Compare
Compare SYRE metrics with: | |||
|---|---|---|---|
Earnings & Growth | SYRE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SYRE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SYRE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SYRE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Spyre Therapeutics, Inc. Income
Spyre Therapeutics, Inc. Balance Sheet
Spyre Therapeutics, Inc. Cash Flow
Spyre Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Spyre Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | Chief Executive Officer & Director |
| Mr. Scott L. Burrows | Chief Financial Officer |
| Ms. Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary |
| Dr. Sheldon Sloan M.B.E., M.D. | Chief Medical Officer |
| Mr. Eric McIntyre | Vice President of Finance & Investor Relations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | Chief Executive Officer & Director | 1990 | 1.05M | |
| Mr. Scott L. Burrows | Chief Financial Officer | Male | 1977 | 716.8K |
| Ms. Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary | Female | 1983 | 568.87K |
| Dr. Sheldon Sloan M.B.E., M.D. | Chief Medical Officer | 1959 | 313.26K | |
| Mr. Eric McIntyre | Vice President of Finance & Investor Relations | Male | -- |
Spyre Therapeutics, Inc. Insider Trades
| Date | 29 May |
| Name | Fairmount Funds Management LLC |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | 29 May |
| Name | Stelzer Laurie |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | 29 May |
| Name | Milligan Sandra |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | 29 May |
| Name | McKenna Mark C. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | 29 May |
| Name | HENDERSON MICHAEL THOMAS |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 29 May | Fairmount Funds Management LLC | Director | Acquired | A-Award | 25000 |
| 29 May | Stelzer Laurie | Director | Acquired | A-Award | 25000 |
| 29 May | Milligan Sandra | Director | Acquired | A-Award | 25000 |
| 29 May | McKenna Mark C. | Director | Acquired | A-Award | 25000 |
| 29 May | HENDERSON MICHAEL THOMAS | Director | Acquired | A-Award | 25000 |